Red Back Mining Inc. (the "Company" or "Red Back") (TSX: RBI) is pleased to report continued Resource growth at its 100% owned Tasiast Gold Mine ("Tasiast") in Mauritania.

Since the previous December 2009 Mineral Resource estimation (February 1, 2010 release) the Measured and Indicated Resource at Tasiast has increased by 2.74Moz to 9.25Moz (a 42% increase) and the Inferred Resource has increased by 0.63Moz to 1.93Moz (a 48% increase) (at cut off grades of 0.2g/t for oxide and 0.5g/t for fresh material).

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

The Phase IIb study will assess Serdaxin’s efficacy as a treatment for major depressive disorder in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will be conducted at multiple sites in the U.S. and will measure the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary efficacy endpoint.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, under its Clinical Trials Agreement with Oncolytics. Oncolytics will provide clinical supplies of REOLYSIN for this study. The Study Chair will be Dr. David E. Cohn of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

The article offers data demonstrating that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.

Orexigen® Therapeutics, Inc. (Nasdaq:OREX ) and Takeda Pharmaceutical Company Limited , today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

Contrave is a combination therapy believed to address both biological and behavioral drivers of obesity. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior.  Orexigen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

RockBridge Resources Inc. (RockBridge- "RBE") (TSX VENTURE: RBE) has entered into an agreement for diamond drilling of the Cross Hills Rare Earth prospect property near Grand Le Pierre, Newfoundland. The Cross Hills property consists of 100% interest in 343 mineral claims covering 20,923 acres, prospective for Rare Earth Elements and metals and for Copper.

New Valley Drilling Co. Ltd. of Springdale, Newfoundland will mobilize equipment to the Cross Hills property shortly, to commence the drilling of targets identified by RockBridge's prospecting program.

Endeavour Silver Corp. (TSX: EDR)(NYSE Amex: EXK)(DBFrankfurt: EJD) announces that it has identified three new silver veins and acquired three new mining properties (click here to see maps) in the San Pedro area of the Guanacevi silver district in Durango State, Mexico.

Endeavour currently owns and operates two high-grade, underground, silver-gold mines in Mexico, the Guanacevi Mines in Durango State and the Guanajuato Mines in Guanajuato State. The Guanacevi Mines produced 622,385 oz silver and 1,602 oz gold (726,515 oz silver equivalents, based on a 65:1 silver:gold ratio) in the 2nd Quarter, 2010, up 40% from Q2, 2009.

Lundin Mining Corporation ("Lundin" or the "Company") (TSX:LUN)(OMX:LUMI) today reported its mineral reserve and resource estimates as at June 30, 2010, six months after the last release as at December 31, 2009. As advised when releasing the December estimates, Lundin has changed the timing of its mineral reserve and resource estimate to align the timing of updates with its annual planning process. Updates will occur annually hereafter.

Continued investment in mine exploration has resulted in the replacement of depletion at both Neves-Corvo and Zinkgruvan and a further increase in the copper mineral resources and reserves at Neves Corvo.

Innocent Inc. ("Innocent" or the "Company") (OTCBB:INCT)), a gold mining company focused in Ecuador, announced today that Global Finishing Ecuador (GFE) has acquired the currently producing Murciealagos Vizcaya and Lilly Rai mining concessions, located in Ecuador's El Oro Province. Innocent Inc. is the majority owner of GFE via its acquisition of 51% of Global Finishing Inc.

According to an independently produced geological report released by Innocent on August 16, 2010, the Murciealagos Vizcaya and Lilly Rai properties conservatively contain 144,492 ounces of inferred gold. However, this resource estimate is based on mining to a depth of only 200 meters.

The report further indicates that the gold veins on the properties may continue to a depth of two kilometers. This suggests the size of the actual gold resource could be substantially larger.

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq: CYPB). The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

"The Staccato system is a broad technology platform and Alexza has more Staccato-based product candidates than we can currently afford to develop on our own. In early July, we outlined our strategy to advance Staccato-based product candidates into development through self-funding and through collaborations," said Thomas B. King, Alexza President and CEO. "Today's announcement of the licensing of our Staccato nicotine technology to Cypress, along with our recently announced plans to advance AZ-007 (Staccato zaleplon) into Phase 2 clinical development, are examples of our execution of this dual-tracked development strategy."

Cereplast, Inc. (NASDAQ: CERP) (“Cereplast,” or the “Company”), a leading manufacturer of proprietary bio-based, compostable and sustainable plastics, announced today that it has entered into a multi-million dollar contract with RI.ME. Masterbatch S.r.l., (“RI.ME.”) based in Mozzate (CO), Italy, to supply bioplastic resins for use in its masterbatch process for adding colorant to bulk, uncolored resins. The new agreement supports RI.ME.’s commitment to offering its customers sustainable, environmental solutions in the design and production of masterbatches.

“We are excited that RI.ME. has chosen Cereplast to provide bioplastic resins for use in its masterbatching process for its clients throughout Europe,” said Mr. Frederic Scheer, Founder, Chairman and CEO of Cereplast, Inc. “This was made possible by RI.ME.’s success in using our materials in its masterbatching process, and by the excellent performance of Cereplast resins on extrusion lines designed for HDPE, LDPE or PVC without any kind of technical investments.

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury. ASIA A refers to a patient with no motor or sensory function in the relevant segments and is considered to be complete paralysis.

"We are filing an application with the FDA to test our spinal cord stem cells in a second medical condition with substantial unmet needs," said Neuralstem CEO and President, Richard Garr. "The proposed trial is primarily designed to test the safety of both our cells and delivery method in chronic spinal cord injury patients."

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Somaxon and Procter & Gamble (NYSE: PG) have entered into a co-promotion agreement for Silenor® (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.

Under the terms of the agreement, Somaxon and Procter & Gamble will co-promote Silenor with a combined 215 sales representatives in the U.S. market. Procter & Gamble’s professional health care sales force will promote Silenor to targeted primary care and other high-prescribing physicians. Somaxon’s focus will be on specialists and other top-decile physicians who treat insomnia. In addition, Procter & Gamble will promote Silenor to targeted pharmacies and will provide supplemental managed care support services for Silenor. Somaxon has also granted Procter & Gamble a right of first negotiation relating to rights to develop and market Silenor as an over-the-counter medication in the U.S.

Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA), a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc. ("3SBio") (NASDAQ: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

The transaction will provide Isotechnika with proceeds of US$6 million. Isotechnika will receive an upfront non-refundable licensing payment of US$1.5 million with an additional US$4.5 million invested by 3SBio through a convertible debenture.

PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP. The regulatory clearance followed PROLOR's submission of an Investigational New Drug (IND) application for hGH-CTP that included preclinical and Phase I clinical data, as well as plans for additional animal studies that the company intends to complete prior to initiation of Phase III trials. The hGH-CTP Phase II clinical program is currently ongoing in various clinical centers in Europe.

Great Basin Gold Ltd, ("Great Basin" or the "Company"), (TSX: GBG; NYSE Amex: GBG; JSE: GBG) announces an updated mineral resource estimate for its Burnstone Project in the Mpumalanga Province, South Africa.

The updated mineral resource estimate, inclusive of all drilling and underground evaluation up to June 30, 2010 and at a range of cutoffs, is tabulated below. At a cutoff of 400 cmg/t the total Measured and Indicated Resources has increased by 3% from approximately 11.7 million ounces to 12.1 million ounces of gold.

- analysis of data from first Phase III clinical trial nearing completion -

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin(TM).

Bioniche and its development partner, Endo Pharmaceuticals Inc. (NASDAQ: ENDP), are in the process of finalizing a protocol for an additional clinical trial - expected to begin enrolling patients in 2010. Details of this new protocol, when finalized, will be made publicly available via the U.S. National Institutes of Health clinical trial registration service at http://www.clinicaltrials.gov.

Cardica, Inc. (Nasdaq: CRDC) today announced that Cardica and Intuitive Surgical, Inc. have entered into a license agreement providing Intuitive with a worldwide, exclusive license to Cardica's intellectual property, which relates to tissue cutting, stapling and clip appliers, for use in the robotics field. Pursuant to the license agreement, Cardica and Intuitive may also enter into future product development agreements.

Intuitive has paid Cardica $12 million for a royalty-bearing license and equity investment in approximately 1.25 million shares of Cardica's common stock. The license excludes vascular anastomosis applications.

Innocent Inc. (OTCBB:INCT), a gold mining company focused in Ecuador, announced today additional information in follow-up to its regulatory filing and press release of August 9, 2010. Innocent reported the findings of an independent geological report on the Murciealagos Vizcaya and Lilly Rai mining concessions in Ecuador's El Oro Province. The entire report can be viewed on the company web site, www.Innocentinc.com.

The report, prepared by independent consultant Mr. Edgar Pillajo G., MBA. P.Eng., conservatively estimates the concessions contain 144,492 ounces of inferred gold and recommends specific mining approaches to enhance exploration and increase production.

Prophecy Resource Corp. ("Prophecy" or the "Company") (TSX VENTURE: PCY)(OTCQX: PRPCF)(FRANKFURT: 1P2) reports today that the Measured and Indicated coal mineral resources within its Chandgana Khavtgai ("Khavtgai") coal project located in east central Mongolia exceeds one billion tonnes of coal.

The resource estimate is based on information from exploration programs completed in 2007 and this year. This year's program included 13 drill holes totaling 2,250 metres of infill drilling, 8 seismic geophysical lines totaling 11.3 km, and total magnetic field mapping of 5.1 sq km. A total of 274 core samples were obtained for analysis.

The exploration program confirmed the continuation of the major coal seam (averaging 37.7 metres) at Khavtgai. Further, the exploration program has increased the confidence in the previously defined Inferred portion of the Khavtgai Project's coal resource in to Indicated and Measured mineral resources.